Endocrinology
News
Sotagliflozin’s HFpEF benefit confirmed by new analyses
News
FIDELIO-DKD: Finerenone cuts new-onset AFib in patients with type 2 diabetes and CKD
News
Dapagliflozin misses as treatment for COVID-19 but leaves intriguing signal for benefit
The SGLT2 inhibitor dapagliflozin was not associated with significant benefit in COVID-19 patients but came close.
Clinical
In-hospital glucose management program gives dramatic savings
“I’ve been advocating for endocrine hospitalists to be deployed nationally,” said Dr. Misha Zilbermint.
News
Weight-related COVID-19 severity starts in normal BMI range, especially in young
News
Most kids with type 1 diabetes and COVID-19 in U.S. fared well
News
Being overweight ups risk of severe COVID-19 in hospital
This research “adds to the known data on the associations between obesity and severe COVID-19 disease and extends these findings” to patients who...
Clinical
Thyroid hormone analogues can reverse NASH
In patients with nonalcoholic steatohepatitis (NASH) and stages 1-3 fibrosis, does the thyroid hormone receptor beta-agonist, resmetirom reduce...
Clinical
Assessing the efficacy and safety of dapagliflozin in patients with HFrEF
Can the use of dapagliflozin, in addition to guideline-directed medical therapy, improve patient-reported outcomes and health-related quality of...
Clinical
Dapagliflozin may cut risk of HF hospitalization in patients with type 2 diabetes
What is the Food and Drug Administration–approved indication for dapagliflozin (Farxiga)?